Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (13877)	9/21/1998 10:02:00 AM
From: BDR	Read Replies (2) \| Respond to of 18691

Datek just responded to my order to short XMIT with a notice that this stock cannot be borrowed. Anyone else have luck with this one.

To: BDR who wrote (13877)	9/21/1998 11:32:00 AM
From: BDR	Read Replies (1) \| Respond to of 18691

SEPR up 4+ (up 20+% in the last week), presumably on this news. Sold Oct 60 covered calls at $5. If they get called away fine, if the stock drops back (usually does), I'm a buyer. Phase III Trials Underway for Desloratadine PR Newswire - September 21, 1998 07:13 MARLBOROUGH, Mass., Sept. 21 /PRNewswire/ -- Sepracor Inc. (Nasdaq: SEPR) today announced that Schering-Plough Corporation (NYSE: SGP) has initiated their Phase III program for desloratadine (previously referred to by Sepracor as descarboethoxyloratadine (DCL)). Desloratadine is an active metabolite of Schering-Plough's CLARITIN(R) brand of antihistamines, the world's leading nonsedating antihistamine, with 1997 sales of approximately $1.7 billion. In December 1997, Schering-Plough Corporation and Sepracor announced a licensing agreement giving Schering-Plough exclusive worldwide rights to Sepracor's patents relating to desloratadine, which in pre-clinical studies has shown the potential for greater potency. Under the terms of the agreement, Sepracor exclusively licensed its desloratadine related patent rights to Schering-Plough, which expects to develop and market a desloratadine product worldwide. Royalties paid to Sepracor will escalate over time and upon the achievement of sales volume and other milestones.